Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine

EJNMMI Research

Table 1 Patient characteristics for PSMA study

Patient	Age (years)	Height (cm)	Weight (kg)	TNM	Initial Gleason score	PSA (ng/ml)
1	68	182	90	T2N1M0	6	13.2
2	76	182	87	T0N1M0 (BCR)	7	1.4
3	82	174	97	T2N0M1	6	14.1
4	66	174	83	T2N0M0	8	7.7
5	75	181	80	T0N1M1 (BCR)	8	2.9
6	74	178	81	T + N0M0 (BCR)	7	3.1
7	64	175	77	T0N0M1 (BCR)	7	8.8
8	74	183	82	T3N0M0	7	19.0
9	72	174	68	T0N1M1 (BCR)	8	1.6
10	73	178	83	T0N0M1 (BCR)	9	0.4

TNM = Clinical stage of prostate cancer, including findings on the baseline PSMA PET/CT; BCR = Biochemical recurrence; PSA = Prostate-specific antigen, measured prior to the baseline PSMA PET/CT